Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus HEATHER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus HEATHER.
ASHLYNA vs HEATHER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
Heather is a combination hormonal contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Drospirenone, a spironolactone analog with anti-mineralocorticoid activity, also inhibits ovulation and may increase cervical mucus viscosity, impeding sperm penetration.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
5 mg orally once daily, increased to 10 mg after 2 weeks if tolerated; maximum 20 mg daily.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal elimination half-life: 4-6 hours. Clinical context: Requires every-6-hour dosing for steady state; therapeutic drug monitoring recommended in renal impairment.
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Renal excretion of unchanged drug (60%) and hepatic metabolism with biliary/fecal elimination (40%).
Category C
Category C
Contraceptive
Contraceptive